Less than half of respondents were “very likely” to refer a patient with EBC for NST based on the following tumor phenotype factors of aggressiveness: ER/PR-negative status (37 %), high histologic grade/histologic type (39 %), HER2-positive status (42 %), and triple-negative status (47 %). Here, ERBB2 is linked to neoplasm.